Pharmaceuticals, Biotechnology and Life Sciences
RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company has made an additional investment in the Series C financing round of Umoja Biopharma (“Umoja”), a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in oncology and autoimmune treatments.
Celadon Pharmaceuticals announced Thursday collaboration with Valeos, a Danish pharmaceutical company, is active and it’s bringing results.
InflaRx N.V. announced Thursday that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome
Santhera Pharmaceuticals said Thursday that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in…
Together with partnering companies SCHOTT Pharma and Körber Pharma, Schreiner MediPharm is going to show how sustainable packaging design can combine waste and cost reduction with user convenience and patient safety.
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.
Novartis said in a press release Monday that the Scottish Medicines Consortium (SMC) has published advice recommending Fabhalta (iptacopan) for…
Cube Biotech and IBA Lifesciences join forces to advance research and production capabilities for the life science industry by leveraging its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.
Clarivate has released the twelfth annual Drugs to Watch report, its guide to the therapies poised to redefine the future of healthcare, highlighting 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
Klinge Biopharma GmbH, the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimilar candidate to Eylea (Aflibercept),has signed a licensing agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. for the semi-exclusive commercialization of FYB203 in major parts of Europe and Israel. In parallel Formycon has signed an agreement with Teva under which Formycon will supply the finished product.